Adam Feuerstein @adamfeuerstein 3h
$GILD Sovaldi scripts 20% week over week growth.
Zacks giving $304 is huge, their very conservative so if they are saying $304 there is good cause folks.
their desperate today.
Fly On The Wall
March 5, 2014
13:02 EDT ARWR Analyst: Arrowhead Research could be in early stages of major run, Barron's says
RBC analyst Michael Yee believes Arrowhead Research is in the early innings of a potentially major run, according to Barron's. Yee cites the company's promising lead drug for Hep B, its RNAi platform technology,and the fact that it could partner with larger firms such as Roche (RHHBY), Bristol Myers (BMY), Merck (MRK), and Novartis (NVS)
Stocks To Watch
Arrowhead Research: ‘Early Innings’ for ‘Major Story’
News and commentary about the stocks you need to know about today
March 5, 2014, 11:50 A.M. ET
By Ben Levisohn